LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company, announced that its stockholders have approved the merger with Alumis Inc. (Nasdaq: ALMS). At a special meeting held today, ACELYRIN stockholders voted in favor of the merger agreement, which stipulates that they will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. The merger aims to create a biopharma company dedicated to developing and commercializing transformative therapies for immune-mediated diseases. The transaction is expected to be completed in the second quarter of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。